ERBB2 and neoplasm: Profiling of phosphorylated ERBB2 and ERBB3 in end-stage tumors indicated that on-target activity of AF was sustained despite tumor progression, pointing to the emergence of alternative resistance mechanisms that could in the future be explored further.